In conclusion, our study demonstrated the pivotal roles of FOXD3-AS1/miR-127-3p/MDM2 regulatory signaling pathways in cisplatin resistance of NSCLC cells (Fig. 7). This evidence concerns the gene FOXD3 and non-small cell lung carcinoma.